131 related articles for article (PubMed ID: 37948595)
1. Tips on choosing a CAR T-cell therapy in DLBCL.
Abramson JS
Clin Adv Hematol Oncol; 2023 Nov; 21(11):592-596. PubMed ID: 37948595
[No Abstract] [Full Text] [Related]
2. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
Zhu H; Deng H; Mu J; Lyu C; Jiang Y; Deng Q
Onco Targets Ther; 2021; 14():4023-4037. PubMed ID: 34239307
[TBL] [Abstract][Full Text] [Related]
4. Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study.
Cheng R; Scippa K; Locke FL; Snider JT; Jim H
Oncol Ther; 2022 Jun; 10(1):123-141. PubMed ID: 34778941
[TBL] [Abstract][Full Text] [Related]
5. Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients.
Nydegger A; Novak U; Kronig MN; Legros M; Zeerleder S; Banz Y; Bacher U; Pabst T
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885182
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
7. Salvage Radiation Treatment for Primary Refractory Diffuse Large B-cell Lymphoma After Chimeric Antigen Receptor (CAR) T-cell Therapy: A Case Report.
Wang K; Prabhu AV; Sasapu A; Lewis GD
Anticancer Res; 2021 Jul; 41(7):3635-3638. PubMed ID: 34230160
[TBL] [Abstract][Full Text] [Related]
8. Influence of
Porpaczy E; Wohlfarth P; Königsbrügge O; Rabitsch W; Skrabs C; Staber P; Worel N; Müllauer L; Simonitsch-Klupp I; Kornauth C; Rohrbeck J; Jaeger U; Schiefer AI
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830747
[TBL] [Abstract][Full Text] [Related]
9. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I; Perry C; Segman Y; Amit O; Bar-On Y; Katz OB; Gold R; Ribakovsky E; Avigdor A; Vainstein V; Goldschmidt N; Ringelstein-Harlev S; Horowitz NA; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Vezker M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Luttwak E; Herishanu Y; Ram R
Ann Hematol; 2022 Apr; 101(4):755-762. PubMed ID: 35083525
[TBL] [Abstract][Full Text] [Related]
10. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
Rentsch V; Seipel K; Banz Y; Wiedemann G; Porret N; Bacher U; Pabst T
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626120
[TBL] [Abstract][Full Text] [Related]
11. Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.
Ping N; Qu C; Li M; Kang L; Kong D; Chen X; Wu Q; Xia F; Yu L; Yao H; Yan L; Wu D; Jin Z
Ann Transl Med; 2022 Mar; 10(6):298. PubMed ID: 35433994
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Broder MS; Ma Q; Yan T; Zhang J; Chang E; Kuzan D; Eldjerou L
Am Health Drug Benefits; 2020; 13(5):192-199. PubMed ID: 33343819
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis.
Cao HH; Wang LL; Geng CK; Mao WW; Yang LL; Ma Y; He M; Zhang R; Zhou YY; Liu LQ; Hu XJ; Yu JX; Yang L; Shen XF; Yin LF; Gu XZ; Shen ZL
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4921-4930. PubMed ID: 32432755
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries.
Canales Albendea MÁ; Canonico PL; Cartron G; Deiters B; Jommi C; Marks R; Rioufol C; Sancho Cia JM; Santoro A; Wagner-Drouet EM
Front Med (Lausanne); 2023; 10():1128295. PubMed ID: 37324138
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
17. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.
Albanyan O; Chavez J; Munoz J
Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886
[TBL] [Abstract][Full Text] [Related]
18. The potential impact of CAR T-cell treatment delays on society.
Thornton Snider J; Brauer M; Kee R; Batt K; Karaca-Mandic P; Zhang J; Goldman DP
Am J Manag Care; 2019 Aug; 25(8):379-386. PubMed ID: 31419095
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy.
Zhu Y; Ai S; Cong M; Jin M; Ma X; Huang H
Ann Hematol; 2023 Mar; 102(3):597-601. PubMed ID: 36710282
[TBL] [Abstract][Full Text] [Related]
20. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]